Granules India Limited · NSE:GRANULES
Granules India — Investor Presentation (July 2019)
16 slides from Granules India's investor presentation, July 2019
Slide 1: Granules India Corporate Presentation
Granules India Corporate Presentation
Slide 2: Vision
Vision To be the global leader in pharmaceutical manufacturing by process innovation and unparalleled efficiencies 2
Slide 3: About Us
About Us • Granules is a pharmaceutical manufacturing company with Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI) and Finished Dosage (FD) facilities • A leader in several key drugs including Paracetamol, Ibuprofen, Metformin, Guaifenesin and Methocarbamol •
Slide 4: Core Business Strategy
Core Business Strategy • Significant market share with large volumes in strategic molecules • Fully integrated in key molecules from APIs to Finished Dosages • Regulatory Filings (ANDAs/Dossier) for Global Markets • Partner with market leaders • Customer specific capacity allocation • Unparalleled e
Slide 5: Infrastructure Overview
Infrastructure Overview • Granules has five facilities as well as two additional facilities through its JVs • Granules’ Facilities (5) 1. Gagillapur – Finished Dosage and PFI 2. Bonthapally – Dedicated Paracetamol API Facility 3. Jeedimetla – Multi-Product API and PFI Facility 4. Bonthapally (Auctus
Slide 6: Gagillapur
Gagillapur • Finished Dosage and PFIs (Pharmaceutical Finished Intermediates) • PFI Capacity: 17,200 TPA • Finished Dosage Capacity: – Tablet/Caplet – 18 billion units / Press-Fits – 500 million units – Coating – 18 billion units – Bulk Packing – As Needed / Bottle Packing – 4 billion units / Bliste
Slide 7: Bonthapally
Bonthapally • Dedicated Paracetamol API Facility • API Capacity: 14,400 TPA • Capabilities: – 5 Paracetamol Grades – 5.2 Ton Batch Size • Regulatory Approvals: – U.S. FDA, EDQM, WHO GMP, ISO 14001:2004 and OHSAS 18001:2007 7
Slide 8: Jeedimetla
Jeedimetla • Multi-Product API and PFI Facility • API Capacity: – Metformin: 2,000 TPA / Guaifenesin: 1,200 TPA / Methocarbamol: 360 TPA • PFI Capacity: 1,200 TPA • Capabilities: – 1.2 Ton PFI Batch Size • Regulatory Approvals: – U.S. FDA, KFDA, TGA, EDQM 8
Slide 9: Jingmen
Jingmen • Dedicated Ibuprofen API Facility • Operated by Granules Biocause (50:50 JV) • API Capacity: 4,800 TPA • Regulatory Approvals: – U.S. FDA, MHRA, EDQM, TGA, KFDA, Russian Health Authority and Health Canada 9
Slide 10: Granules OmniChem
Granules OmniChem • Multi-Product API Facility • Operated by Granules OmniChem(50:50 JV) • Focused on CRAMs 10
Slide 11: Auctus Pharma
Auctus Pharma • In 2013, Granules announced the acquisition of Auctus Pharma, the deal closed in February 2014 • Auctus has an API site in Vizag and an intermediate site in Hyderabad • Currently manufactures 20 APIs in several therapeutic sectors such as Antihistaminic, Antihypertensive, Antithrombo
Slide 12: Revenue Trend
Revenue Trend 1,293 1,096 764 654 475 FY 11 FY 12 FY 13 FY 14 FY 15 12
Slide 13: FY15 Revenue by Geography
FY15 Revenue by Geography AMEA USA 10% CANADA 26% 6% LATAM EUROPE 11% 31% INDIA 16% 13
Slide 14: FY15 Revenue by Business Vertical
FY15 Revenue by Business Vertical FD 32% API 44% PFI 24% 14
Slide 15: Granules Leadership Team
Granules Leadership Team Mr. C. Krishna Prasad – Chairman & Managing Director Mr. Prasad is the Founder of Granules and has three decades of experience in the pharmaceutical industry. In 1984, he set up a Paracetamol manufacturing facility, focused on capital and process efficiency and his company b
Slide 16: Thank You
Geranutes THANK YOU 16